Brooklyn Immunotherapeutics Announces Executive Management Changes
Executive Officer and President. He will replace Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President, who departs to focus on building a new venture. The Company also announces the appointment of Andrew Jackson as Chief Financial Officer.